Literature DB >> 23986097

Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients.

Liene Elsone1, Jay Panicker, Kerry Mutch, Mike Boggild, Richard Appleton, Anu Jacob.   

Abstract

Prompt treatment of neuromyelitis optica (NMO) relapses with steroids or plasma exchange (PLEX) often prevents irreversible disability. The objective of this study is to report the use of intravenous immunoglobulins (IVIG) as treatment for acute relapses in NMO. A retrospective review of 10 patients treated with IVIG for acute relapses was conducted. IVIG was used in the majority of cases because of lack of response to steroids with/without PLEX. Improvement was noted in five of 11 (45.5%) events; the remaining had no further worsening. One patient, a 79-year-old woman, had a myocardial infarction seven days after IVIG. IVIG may have a role in treating acute NMO relapses.

Entities:  

Keywords:  NMO; Neuromyelitis optica; acute treatment; aquaporin 4; intravenous immunoglobulins; relapse

Mesh:

Substances:

Year:  2013        PMID: 23986097     DOI: 10.1177/1352458513495938

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  39 in total

1.  Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis.

Authors:  Maria Stavrou; Lucy Francis; Nomathamsanqa Tshuma; Klaus Schmierer
Journal:  BMJ Case Rep       Date:  2018-05-23

Review 2.  Neuromyelitis optica spectrum disorders associated with other autoimmune diseases.

Authors:  Eduardo Freitas; Joana Guimarães
Journal:  Rheumatol Int       Date:  2014-06-22       Impact factor: 2.631

3.  Rescue effects of intravenous immunoglobulin on optic nerve degeneration in a rat model of neuromyelitis optica.

Authors:  Sho Nobuyoshi; Akiyasu Kanamori; Yoshiko Matsumoto; Makoto Nakamura
Journal:  Jpn J Ophthalmol       Date:  2016-06-07       Impact factor: 2.447

Review 4.  Neuromyelitis optica spectrum disorders.

Authors:  Eoin P Flanagan; Brian G Weinshenker
Journal:  Curr Neurol Neurosci Rep       Date:  2014-09       Impact factor: 5.081

Review 5.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

6.  Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica.

Authors:  Julien Ratelade; Alex J Smith; A S Verkman
Journal:  Exp Neurol       Date:  2014-03-14       Impact factor: 5.330

Review 7.  Treatment of neuromyelitis optica: state-of-the-art and emerging therapies.

Authors:  Marios C Papadopoulos; Jeffrey L Bennett; Alan S Verkman
Journal:  Nat Rev Neurol       Date:  2014-08-12       Impact factor: 42.937

8.  Intravenous immunoglobulin as the rescue treatment in NMOSD patients.

Authors:  Jie Lin; Binbin Xue; Ruofan Zhu; Juyuan Pan; Jia Li; Yan Lin; Xiang Li; Junhui Xia
Journal:  Neurol Sci       Date:  2021-02-01       Impact factor: 3.307

Review 9.  Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.

Authors:  J Nicholas Brenton; Brenda L Banwell
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 10.  Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Authors:  Ingo Kleiter; Ralf Gold
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.